Bristol-Myers Squibb is the latest pharmaceutical company to access Santaris Pharma’s locked nucleic acid (LNA) technology for the discovery and development of RNA-targeted therapies. Santaris believes that its platform is able to overcome the limitations of earlier antisense and siRNA technologies by enabling the development of single-stranded oligonucleotides that are small in size and have high affinity to disease-related messenger RNA (mRNA) and microRNA (miRNA) targets. These LNA-based drug candidates are able to penetrate multiple tissues, thus allowing for systemic delivery. The company’s other collaborators include Enzon Pharmaceuticals, Pfizer, GlaxoSmithKline, Shire and miRagen Therapeutics.